Sunshine Biopharma (NASDAQ:SBFM) stock is shining brighter on Tuesday after revealing the effects its mRNA molecules have against cancer.
Two of the mRNA molecules developed by Sunshine Biopharma were shown to be effective in destroying cancer cells grown in culture. The company notes that this saw the molecules wiping out cancer cells from multiple different types of the disease, including those resistant to drugs.
In addition to that, Sunshine Biopharma notes that toxicity studies of the mRNA molecules were positive. That includes little to no cytotoxic effects in non-transformed human cells.
According to Sunshine Biopharma, these results show the promise its mRNA molecules have in treating patients with cancer. It also notes that they are ready to be delivered via mRNA vaccine technology.
That’s a massive win for SBFM stock, but it still might take some time to get these to market. The company notes that it has yet to file patents on these two mRNA molecules. We’ll also have to wait and see what the U.S. Food and Drug Administration (FDA) has to say about them.
Even so, that’s not stopping investors from diving into SBFM stock with heavy trading on Tuesday. As of this writing, more than 90 million shares of the company’s stock have been traded. That’s quite the jump over its daily average trading volume of roughly 2.7 million shares.
SBFM stock is up 146.9% as of Tuesday morning.
There’s more stock market news for traders to jump into below!
We’ve got all the hottest stock news traders need to know about today. Among that is what’s happening with Aterian (NASDAQ:ATER) stock, a breakdown of Twitter (NYSE:TWTR) stock, as well as what’s happening with cruise stocks on Tuesday. You can find all of this info at the following links!
More Tuesday Stock Market News
- ATER Stock Alert: 7 Things to Know as Aterian Rockets Higher
- Is Twitter (TWTR) Stock a Buy Right Now?
- Cruise Stocks News: Why Are CCL, RCL, NCLH Stocks Up Today?
On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.
With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That’s because these “penny stocks” are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that InvestorPlace.com’s writers disclose this fact and warn readers of the risks.
Read More: Penny Stocks — How to Profit Without Getting Scammed
